Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sylvia Hsu

Dermatology Philadelphia, PA Medical Doctor

NPI 1548340805 CMS profile 297470

3401 N Broad St, Philadelphia, PA 19140

Open in the dashboard

General payments

$40,726

100 records reported · program years 2019–2025

Research payments

$1,866

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$218,987 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Sylvia Hsu of Philadelphia, PA is reported in the CMS Open Payments database as having received $40,726 across 100 general payments and $1,866 in research payments paid to them. Separately, studies naming them as principal investigator received $218,987 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $525 25
2024 General $11,895 8
2023 General $4,124 2
2022 General $4,930 15
2022 Research $1,866 1
2021 General $4,253 12
2020 General $5,928 7
2019 General $9,072 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sylvia Hsu
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Sylvia Hsu were reported at $525. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Sylvia Hsu Dermatology median Middle half National median
2019 $9,072 $454 $129–$1,240 $163
2020 $5,928 $235 $81–$756 $114
2021 $4,253 $377 $108–$1,108 $132
2022 $4,930 $514 $143–$1,391 $149
2023 $4,124 $607 $159–$1,674 $160
2024 $11,895 $751 $204–$1,903 $164
2025 $525 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $9,431 17 payments
  2. Galderma Laboratories, L.P. $8,163 1 payment
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $6,066 4 payments
  4. Lilly USA, LLC $4,638 4 payments
  5. Genzyme Corporation $4,421 6 payments
  6. Ortho Dermatologics, a division of Bausch Health US, LLC $3,534 2 payments
  7. LEO Pharma Inc. $2,380 2 payments
  8. AbbVie, Inc. $1,003 38 payments
  9. Novartis Pharmaceuticals Corporation $350 7 payments
  10. Regeneron Healthcare Solutions, Inc. $140 4 payments
  11. Other $600 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $37,207 11 payments
  2. Food and Beverage $2,941 86 payments
  3. Travel and Lodging $579 3 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $9,511 18 payments
  2. DUPIXENT Immunology $4,374 3 payments
  3. SPEVIGO $4,122 2 payments
  4. ADBRY $2,280 1 payment
  5. RINVOQ $452 24 payments
  6. SKYRIZI Immunology $383 11 payments
  7. COSENTYX $238 4 payments
  8. SKYRIZI Immunology $152 2 payments
  9. STELARA $146 2 payments
  10. DUPIXENT Inflammation And Immunology $140 4 payments
  11. Other $878 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $1,866 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

287

Median for Dermatology: 534

Drug cost

$1,534,962

Median for Dermatology: $67,151

Branded share of claims

94.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 81 $680,510
Dupixent Pen Dupilumab Brand 104 $372,980
Humira Pen Adalimumab Brand 17 $181,593
Cosentyx Sensoready (2 Pens) Secukinumab Brand 14 $93,975
Humira(Cf) Adalimumab Brand 11 $74,927
Xolair Omalizumab Brand 25 $66,245
Dupixent Syringe Dupilumab Brand 18 $64,668
Hydrocortisone Generic 17 $63

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$58,664

Medicare's payments for the services billed

Medicare patients

586

Average age 67

Services billed

1,259

337 women, 249 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 41%
Chronic kidney disease 29%
Ischemic heart disease 25%
Depression 25%
COPD 21%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $77
$77 — —
SKYRIZI
  • AbbVie, Inc. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

101 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record